FOQUEST
As listed in the register: FOQUEST
35 mg · capsule (controlled-release)
- Prescription only
- Pain, sleep, mood, epilepsy and the brain
- Active substance
- Methylphenidate Hydrochloride
- Made by
- Elvium Life Sciences
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Cotempla XR-ODT). It describes the substance, not this exact product.
Methylphenidate is a central nervous system (CNS) stimulant.
The mode of therapeutic action in ADHD is not known.
In humans, methylphenidate is metabolized primarily via deesterification to alpha-phenyl-piperidine acetic acid (ritalinic acid).
After oral administration of radiolabeled methylphenidate in humans, methylphenidate was extensively metabolized and approximately 80% of the radioactivity was excreted in the urine in the form of PPAA.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2025-09-24
Safety of the active substance
From the US prescribing label for the same active substance (Cotempla XR-ODT). It describes the substance, not this exact product.
WARNING: ABUSE, MISUSE, AND ADDICTION COTEMPLA XR-ODT has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction.
- COTEMPLA XR-ODT is contraindicated in patients with: Known hypersensitivity to methylphenidate or other components of COTEMPLA XR-ODT.
- Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate products [see Adverse Reactions (6.2) ].
- Concomitant treatment with monoamine oxidase inhibitors (MAOIs), and also within a minimum of 14 days following discontinuation of treatment with a monoamine oxidase inhibitor because of the risk of hypertensive crisis [see Drug Interactions (7.1) ].
- Known hypersensitivity to methylphenidate or product components.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
European UnionNo exact match for this strength and form
SpainNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Elvium Life Sciences |
|---|---|
| Active substance | Methylphenidate Hydrochloride |
| Used in | Pain, sleep, mood, epilepsy and the brain |
| Strength | 35 mg |
| Form | capsule (controlled-release) |
| Classification | N06BA04 · Pain, sleep, mood, epilepsy and the brain |
| Route | oral |
| Dispensing (as stated by the register) | CONTROLLED DRUGS (CDSA III) |
| Status | Marketed |
| Marketed | Yes, according to the register |
| DIN | 02470306 |
| DPD drug code | 95928 |
Source: Drug Product Database · 2026-09-30 · not reviewed by a clinician
Contains information licensed under the Open Government Licence – Canada. Reuse terms: Open Government Licence – Canada.
Other strengths and forms
7 products are sold under this name. Grouped by form; a number on a strength means several companies make it.
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.